LGD4033 LGD-4033 Ligandrol CAS: 1165910-22-4

CAS NO: 1165910-22-4
LGD4033 LGD-4033 Ligandrol
Chemical Name: LGD4033/LGD-4033
Molecular Formula: C14H12F6N2O
Formula Weight: 338.248 g/mol
CAS No: 1165910-22-4
Description Review
Description

LGD4033 is a selective androgen receptor modulator (SARM) that is known for its ability to increase muscle mass and improve athletic performance. This non-steroidal compound works by selectively binding to androgen receptors in the muscles and bones, leading to increased protein synthesis and enhanced muscle growth.

Ligandrol LGD-4033 Selective androgen receptor modulator

Health Benefits:

LGD4033 has been found to have several health benefits, including increased muscle mass and strength, improved bone density, and enhanced athletic performance. Additionally, it has been found to improve overall well-being, increase energy levels, and decrease the risk of serious medical conditions such as osteoporosis and muscle wasting.

Potential Effects:

LGD4033 is known to have potent muscle-building effects, making it a popular choice among athletes and bodybuilders. It has been shown to increase muscle mass and strength, while also enhancing athletic performance and endurance. Additionally, it has been found to improve bone density and reduce the risk of osteoporosis.

Mechanisms:

LGD4033 works by selectively binding to androgen receptors in the muscles and bones, leading to increased protein synthesis and enhanced muscle growth. Additionally, it has been found to improve bone density by stimulating osteoblast activity, which is responsible for bone formation.

Safety:

While LGD4033 has been found to be generally safe, there are some potential side effects that should be considered before use. These include an increase in acne, hair growth, and changes in libido. Additionally, it may affect liver and kidney function, and as such, it should only be used under the guidance of a qualified medical professional.

Side-Effects:

Some potential side effects associated with LGD4033 include an increase in acne, hair growth, and changes in libido. Additionally, it may affect liver and kidney function.

Dosage Information:

The recommended dosage of LGD4033 varies depending on the intended use. However, for muscle-building purposes, a dosage of 10mg per day is typically recommended. These dosages should only be used under the guidance of a qualified medical professional to ensure maximum safety and effectiveness.

In conclusion, LGD4033 is a potent and effective selective androgen receptor modulator that has been found to have several health benefits, including increased muscle mass and strength, improved bone density, and enhanced athletic performance. While it is generally safe, potential side effects should be considered before use, and it should only be used under the guidance of a qualified medical professional.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code